MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation in total knee arthroplasty surgery. In addition, its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. It has strategic collaborations with AbbVie to develop, manufacture, and commercialize six long-acting injectable therapeutic products; and IM4TB to develop a long-acting injectable version of Macozinone for the treatment of tuberculosis. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.
Frequently asked questions
What sector does Medincell SA (MEDCL) operate in?
Medincell SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Medincell SA (MEDCL) current stock price?
As of the latest data, Medincell SA stock price is €24.50, with a previous close of €24.50.
What is Medincell SA (MEDCL) current market capitalization?
Medincell SA market cap is approximately 879.83 million.
What is Medincell SA (MEDCL) Earnings Per Share (EPS)?
The trailing EPS is -€0.94, and the forward EPS is €0.19.
What is Medincell SA (MEDCL) EBITDA?
Medincell SA EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.50 million.
Does Medincell SA (MEDCL) pay dividends?
No. Medincell SA does not pay a dividend.
When is Medincell SA (MEDCL) next earnings report?
Medincell SA is expected to release its next earnings report on September 30, 2026.
What is Medincell SA (MEDCL) beta (volatility) score?
Medincell SA has a beta of 0.978, meaning its volatility is roughly in line with the market.
